Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Metamark Genetics logo — Metamark - A leader in comprehensive urology cancer care

Metamark Genetics

Metamark - A leader in comprehensive urology cancer care

Founded 2007 United States Cambridge, United States 23 employees Growth Total: $33.80M Biotechnology, Health Care +1

General Information

Company Name Metamark Genetics
Founded Year 2007
Location United States Cambridge, United States
Founders / Decision Makers
Team member
Employees 23
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Growth
Social

BounceWatch is an independent company data service, not affiliated with Metamark Genetics. To contact Metamark Genetics, visit metamarkgenetics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Metamark Genetics compare?

A PDF of Metamark Genetics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Metamark Genetics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Metamark Genetics

Metamark Genetics, established in 2007, positions itself as a frontrunner in the field of comprehensive urology cancer care. With its slogan "Metamark - A leader in comprehensive urology cancer care," the company is anchored in breakthrough diagnostic and prognostic testing aimed at enhancing cancer treatment outcomes.

Headquartered in the United States, Metamark operates within the Biotechnology, Health Care, and Health and Wellness industries. Since inception, the firm has made significant strides in clinical proteomics, focusing particularly on prostate and bladder cancer, leveraging its deep expertise in molecular diagnostics.

The company last secured a $13.00M Series B investment on 05 November 2012, which supports its ongoing innovation and expansion endeavors.

Business keywords: Urology Cancer Care, Prostate Cancer Diagnosis, Bladder Cancer Management, Clinical Proteomics, Molecular Diagnostics, Personalized Medicine, Prognostic Testing, Predictive Diagnostic Tests, Prognosis Determinants Platform, ProMark, Cancer Progression Analysis, Metastasis Research, Tumor Stratification

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Growth Equity VC $9.10M -
01 Nov 2012
Series B $22.00M 1
Perseus, L.L.C.
Perseus, L.L.C.
01 Aug 2010
Early VC $2.70M -
01 May 2009

Metamark Genetics Alternatives & Competitors

View All Alternatives
Metamark Genetics vs
mdxhealth
mdxhealth United States

Molecular Diagnostic Solutions for Prostate Cancer

Post-IPO Equity
262 employees
Biotechnology, Health Care
Metamark Genetics vs
Crescendo Bioscience
Crescendo Bioscience

Empowering rheumatologists with precise diagnostic tools for autoimmune and inflammatory disease man...

Series D
1001-5000 employees
Biotechnology, Health Care
Metamark Genetics vs
3DMedcare
3DMedcare United States

We are dedicated to providing precision diagnosis solutions to any patient, anytime, anywhere.

Series D
113 employees
Biopharma, Biotechnology
Also compare with: Metamark Genetics vs MultiplexDX International MultiplexDX International Metamark Genetics vs Biocept, Inc. Biocept, Inc. View all alternatives

FAQ About Metamark Genetics

Metamark - A leader in comprehensive urology cancer care
Metamark Genetics was founded in 2007.
Metamark Genetics is headquartered in Cambridge, United States.
Metamark Genetics operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Urology Cancer Care, Prostate Cancer Diagnosis, Bladder Cancer Management and Clinical Proteomics.
Metamark Genetics has approximately 23 employees.
Metamark Genetics has completed 3 funding rounds, raising a total of $33.80M. The latest funding stage is Growth.
Top alternatives and competitors to Metamark Genetics include mdxhealth, Crescendo Bioscience, 3DMedcare, Empire Genomics, MultiplexDX International. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Metamark Genetics and mdxhealth are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Metamark Genetics, https://bouncewatch.com/company/metamark-genetics, updated 4 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes